Pharmacological Management of Parkinson's Disease:
A Neurologist's Evidence-Based Overview

1. The Goal of Pharmacotherapy

A fundamental principle of Parkinson's disease pharmacotherapy is symptom management rather than disease modification. No currently available agent has demonstrated convincing neuroprotective efficacy in adequately powered randomized controlled trials. The therapeutic objective is therefore to maintain the patient's functional capacity and quality of life by compensating for progressive dopaminergic deficit.

This distinction is clinically important: patients and caregivers should understand that medication optimizes symptomatic control but does not arrest the underlying neurodegenerative process. This reality reinforces the importance of complementary non-pharmacological approaches, particularly structured exercise, which does have emerging evidence for disease-modifying potential.

2. Levodopa: The Gold Standard

Levodopa, introduced by Cotzias and colleagues in the late 1960s, remains the most efficacious symptomatic agent for Parkinson's disease more than half a century after its development. As the metabolic precursor to dopamine, levodopa crosses the blood-brain barrier and undergoes decarboxylation to dopamine in nigrostriatal terminals and, progressively, in non-neuronal cells.

To minimize peripheral dopaminergic side effects and maximize CNS bioavailability, levodopa is invariably co-administered with a peripheral aromatic amino acid decarboxylase (AAAD) inhibitor — carbidopa (common in Asian and North American markets) or benserazide (common in Europe). This combination reduces the required levodopa dose by approximately 75% and substantially reduces nausea.

3. The Levodopa Initiation Question

The question of when to initiate levodopa has been a subject of considerable clinical debate. Earlier reluctance stemmed from the observation that long-term levodopa use is associated with motor complications — wearing-off and dyskinesia — thought to reflect pulsatile, non-physiological dopaminergic stimulation.

Contemporary evidence, however, has shifted clinical practice toward a more pragmatic approach. The LEAP trial (Verschuur et al., NEJM 2019) demonstrated no significant difference in outcomes between early and delayed levodopa initiation, challenging the rationale for withholding treatment. Current consensus supports initiating pharmacotherapy when symptoms cause functional impairment, with individualized timing based on the patient's age, disease severity, occupational demands, and preferences.

4. Dopamine Agonists

Dopamine agonists (pramipexole, ropinirole, rotigotine, piribedil) act directly on striatal dopamine receptors, bypassing the requirement for surviving presynaptic terminals. They offer a longer duration of action than levodopa and, critically, are associated with a lower incidence of dyskinesia due to more continuous receptor stimulation.

Their primary limitations include inferior symptomatic efficacy compared to levodopa, and a distinct side-effect profile including somnolence, pedal edema, and — importantly — impulse control disorders (pathological gambling, hypersexuality, compulsive eating) in a clinically significant minority. Dopamine agonists are generally preferred as initial monotherapy in younger patients (under 70), in whom the long treatment horizon makes dyskinesia risk more clinically relevant.

5. MAO-B Inhibitors

Monoamine oxidase type B (MAO-B) inhibitors — selegiline and rasagiline — reduce dopamine catabolism in the brain by inhibiting the principal enzyme responsible for central dopamine breakdown, producing a modest but clinically meaningful prolongation of dopaminergic transmission. MAO-B inhibitors are used as monotherapy in early disease or as adjunctive agents alongside levodopa. Rasagiline attracted particular interest due to early signals of possible neuroprotection in the ADAGIO trial, though subsequent analysis could not conclusively distinguish neuroprotective from symptomatic effects.

6. COMT Inhibitors and the Wearing-Off Phenomenon

With advancing disease, a majority of levodopa-treated patients develop motor fluctuations — the most common being "wearing-off," in which the therapeutic effect of each levodopa dose diminishes before the next scheduled dose. This reflects both the shortening of levodopa's plasma half-life effect as disease advances and the loss of presynaptic buffering capacity.

Catechol-O-methyltransferase (COMT) inhibitors — entacapone, tolcapone, and opicapone — reduce peripheral levodopa degradation, extending its plasma half-life and smoothing motor fluctuations. Systematic assessment of the temporal relationship between symptoms and medication timing is essential for identifying wearing-off and guiding adjustment.

7. Integrated Management

Pharmacotherapy represents one pillar of Parkinson's disease management. Evidence increasingly supports the integration of structured exercise, sleep optimization, nutritional support, and psychological care alongside drug treatment. The rationale for this integrative approach rests on the distinct and complementary mechanisms through which pharmacological and non-pharmacological interventions act on the dopaminergic system and its environment.